Laparoscopic Antireflux Sx May Provide Added Benefits in GERD

This article originally appeared here.
Share this content:
Laparoscopic Antireflux Sx May Provide Added Benefits in GERD
Laparoscopic Antireflux Sx May Provide Added Benefits in GERD

WEDNESDAY, May 4, 2016 (HealthDay News) -- Laparoscopic antireflux surgery (LARS) and esomeprazole are both beneficial for patients with chronic gastroesophageal reflux disease (GERD), but surgery may have an edge, according to research published in the May issue of Clinical Gastroenterology and Hepatology.

Jan G. Hatlebakk, M.D., Ph.D., from the Haukeland University Hospital in Bergen, Norway, and colleagues examined data from a prospective trial to compare the efficacy and safety of LARS (116 patients) versus esomeprazole (20 or 40 mg/day; 151 patients) over five years. Ambulatory intraesophageal and intragastric 24-hour pH monitoring data were compared before the start of treatment and six months and five years later.

The researchers found that the median 24-hour esophageal acid exposure was 8.6 percent at baseline and 0.7 percent after six months and five years (P < 0.001 versus baseline) in the LARS group. The corresponding values were 8.8, 2.1, and 1.9 percent in the esomeprazole group (P < 0.001 for therapy versus baseline and for LARS versus esomeprazole). In both groups, gastric acidity was stable. More severe supine reflux at baseline was seen in patients who required a dose increase to 40 mg/day esomeprazole; after dose escalation, they also had decreased esophageal acid exposure (P < 0.02) and gastric acidity.

"Esophageal acid reflux was reduced greatly by LARS or esomeprazole therapy," the authors write. "However, patients receiving LARS had significantly greater reductions in 24-hour esophageal acid exposure after six months and five years."

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures esomeprazole and funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »